Summary of Intensity Therapeutics Conference Call Company Overview - **Company**: Intensity Therapeutics, Inc. (NasdaqCM: INTS) - **Focus**: Development of INT230-6, a novel intratumoral chemotherapy drug aimed at treating solid tumors Key Industry Insights - **Industry**: Oncology, specifically focusing on innovative cancer therapies - **Technology**: INT230-6 combines sodium hydroxybenzoyl amlodipine (SHAU) with cisplatin and vinblastine, designed to enhance drug delivery and immune response within tumors [5][6][8] Core Points and Arguments 1. **Clinical Study Overview**: The IT01 study evaluated INT230-6 in metastatic refractory patients with solid tumors, highlighting a novel approach to intratumoral chemotherapy [10][11] 2. **Dosing Strategy**: Dosing was personalized based on tumor size, with a maximum of 175 milliliters administered safely [11][12] 3. **Safety Profile**: INT230-6 demonstrated a favorable safety profile with no dose-limiting toxicities reported, and most adverse events were mild [16][17] 4. **Efficacy Results**: - Disease control rate was 75% for monotherapy, with 83% for patients receiving 40% or more of their tumor burden injected [18][19] - Median overall survival was approximately 12 months, significantly higher than the historical average of 4 to 7 months for similar treatments [22][23] 5. **Immune Response**: The treatment induced infiltration of activated immune cells in the tumor microenvironment, suggesting a systemic anti-tumor effect [30][31] 6. **Study Limitations**: The study was not randomized and had a limited patient number, which may affect the generalizability of the results [31] Additional Important Information - **Future Steps**: The company is seeking approximately $25 million in funding to restart a paused Phase 3 trial, which has already received regulatory approval in eight countries [40][42] - **Combination Studies**: There are ongoing studies combining INT230-6 with immunotherapy agents, although results from these cohorts were not included in the current publication [45][46] - **Patient Demographics**: The study included a diverse range of solid tumor types, with sarcoma being the most common [14][25] Conclusion - INT230-6 shows promise as a novel treatment for solid tumors, with a favorable safety profile and encouraging efficacy results. The company is actively seeking funding to advance its clinical trials and further explore the potential of this innovative therapy.